Can tranexamic acid (TXA) stop a gastrointestinal (GI) bleed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Tranexamic acid (TXA) should not be used as a primary treatment to stop a gastrointestinal (GI) bleed. While TXA is an antifibrinolytic agent that helps prevent blood clot breakdown and is effective for certain types of bleeding, its role in GI bleeding is limited. For acute GI bleeds, standard treatments include proton pump inhibitors (such as pantoprazole 40mg IV twice daily), endoscopic interventions, and blood product transfusions as needed. According to the most recent and highest quality study 1, TXA has been evaluated in a large randomized placebo-controlled trial including 12,009 patients with acute upper gastrointestinal bleeding, and no beneficial effect of TXA was observed in the whole group nor in the subgroup analysis of patients with suspected variceal bleeding and liver disease comorbidity. Additionally, there are concerns about potential side effects including thrombotic complications when used for GI bleeding, as noted in the study 1.

Some key points to consider when managing GI bleeding include:

  • Standard treatments such as acid suppression, endoscopic therapy, and addressing the underlying cause are recommended
  • TXA may provide modest benefits in certain cases, but the evidence isn't strong enough to support routine use
  • There are concerns about potential side effects including thrombotic complications when used for GI bleeding
  • The use of TXA in GI bleeding is not recommended, as stated in the guidelines 1 and 1.

In terms of specific patient populations, such as those with cirrhosis, the guidelines recommend against the use of TXA in patients with cirrhosis and active variceal bleeding 1. Instead, portal hypertension-lowering drugs and endoscopic treatment should be used to achieve haemostasis, and correction of haemostatic abnormalities should not be indicated unless there is failure to control haemorrhage.

Overall, the evidence suggests that TXA should not be used as a primary treatment to stop a GI bleed, and instead, standard treatments and guidelines should be followed.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.